CHD6

Overview

CHD6 (Chromodomain Helicase DNA Binding Protein 6) is a member of the CHD family of ATP-dependent chromatin remodelers. It is among the large set of chromatin-remodeling genes found to be recurrently mutated in bladder transitional cell carcinoma (TCC), reflecting a broadly disrupted epigenetic landscape in that cancer type.

Alterations observed in the corpus

Mutation in bladder TCC as part of a chromatin-remodeling gene cluster altered in 58% of cases PMID:24121792

Cancer types (linked)

BLCA: somatic mutation; part of a 58% chromatin-remodeling gene alteration burden in TCC PMID:24121792

Co-occurrence and mutual exclusivity

Co-occurs with mutations in KDM6A, ARID1A, KMT2A/C/E, EP300, EP400, CREBBP, NCOR1, SMARCA4, KDM5A/B as part of the chromatin-remodeling alteration set in TCC PMID:24121792

Therapeutic relevance

No direct drug targets reported in the current corpus; chromatin remodeling pathway disruption in TCC is a candidate for epigenetic therapy investigation.

Open questions

Precise mutation frequency and functional role of CHD6 in TCC pathogenesis are not yet characterized.

Sources

PMID:24121792

This page was processed by crosslinker on 2026-05-09.